DHR Danaher Corporation

Q3 2025 10-Q

Filed: Oct 21, 2025Period ending Sep 26, 2025

Health Care

Industrial Instruments For Measurement, Display, and ControlSEC EDGAR

Danaher Corporation (DHR) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Oct 21, 2025 for the fiscal period ending Sep 26, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.

AI Filing Analysis
Q3 2025 10-Q

Management Discussion & Analysis

• Revenue $6.05B Q3 2025, up 4.5% YoY; Nine months $17.73B, up 2.5% YoY, driven by Biotechnology and Diagnostics growth
• Operating margin 19.1% Q3 2025 vs 16.5% YoY (+260 bps); Nine months margin 18.0% vs 19.8% YoY (-180 bps) due to impairments

+3 more insights

Risk Factors

• New trade policy risk due to U.S. tariffs and retaliatory tariffs impacting supply costs and pricing competitiveness
• Material update on tariffs includes August 2025 U.S. Court ruling against certain tariffs, pending U.S. Supreme Court review

+3 more insights

Quarterly Financial Summary
XBRL

Revenue

$6.1B

▲ +4.4% YoY▲ +2.0% QoQ

Net Income

$908M

▲ +11.0% YoY▲ +63.6% QoQ

Gross Margin

58.2%

▼ -46bp YoY▼ -115bp QoQ

Operating Margin

19.1%

▲ +254bp YoY▲ +626bp QoQ

Net Margin

15.0%

▲ +89bp YoY▲ +565bp QoQ

ROE

1.8%

Total Assets

$79.9B

EPS (Diluted)

$1.27

▲ +13.4% YoY▲ +62.8% QoQ

Operating Cash Flow

$1.7B

▲ +9.8% YoY▲ +24.2% QoQ

Source: XBRL data from Danaher Corporation Q3 2025 10-Q filing on SEC EDGAR. All figures in USD.

Other Danaher Corporation Quarterly Reports

Q2 2025 10-Q

Q1 2025 10-Q

Get deeper insights on Danaher Corporation

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.